Entropy Technologies LP Sells 15,354 Shares of Cencora, Inc. (NYSE:COR)

Entropy Technologies LP lessened its position in shares of Cencora, Inc. (NYSE:COR) by 62.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,194 shares of the company’s stock after selling 15,354 shares during the period. Entropy Technologies LP’s holdings in Cencora were worth $2,069,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. New Millennium Group LLC bought a new position in shares of Cencora during the second quarter worth about $26,000. TCTC Holdings LLC bought a new position in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the first quarter valued at approximately $30,000. MFA Wealth Advisors LLC bought a new stake in shares of Cencora in the second quarter worth $30,000. Finally, Concord Wealth Partners acquired a new position in Cencora during the third quarter worth $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Bank of America reissued a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company increased their price objective on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.1 %

COR stock opened at $248.77 on Wednesday. The business’s 50 day simple moving average is $232.24 and its 200 day simple moving average is $230.86. Cencora, Inc. has a 1-year low of $191.11 and a 1-year high of $251.56. The firm has a market capitalization of $49.02 billion, a PE ratio of 33.13, a PEG ratio of 1.61 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Friday, November 15th. Cencora’s payout ratio is currently 27.16%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.